Trophea is a start-up company developing an innovative medication against skin atrophy.
Trophea AB and its subsidiary Trophea Development AB were founded in 2016. Trophea Development AB develops a topical product for the treatment of skin atrophy caused by long-term use of corticosteroids. There is currently no effective treatment for skin atrophy.
The majority owner Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB changed its name to AQILION AB in the beginning of 2019. The name change marks a new phase in the development of the company, with a new strategy and identity.
Aqilion is a Swedish life science company that focuses on pharmaceutical projects with potential to improve quality of life for patients, while generating value for health services and society.
Read more at www.aqilion.com.